Geldanamycin, an antibiotic derived from Streptomyces hygroscopicus, was the first identified HSP90 inhibitor [36] [37],while ganetespib is a synthetic HSP90 inhibitor currently in Phase 3 clinical trial in cancer patients [14]. Here, HSP90AB1 is linked to cancer.